Portfolio company
Uncommon Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops gene-based medicines for patients with rare neurodevelopmental disorders, with an initial focus on treating Rett Syndrome.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Neurogene Inc
This company develops genetic medicines and gene therapies to treat patients and families affected by rare neurological diseases including Rett syndrome and Batten disease.
Mahzi Therapeutics
This biotechnology company develops gene and antisense oligonucleotide therapies for patients with rare genetic neurodevelopmental disorders.
Vico Therapeutics
This company develops antisense oligonucleotide therapies to treat patients with rare genetic neurological disorders, including Huntington's disease and spinocerebellar ataxias.
Stridebio
This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.
Encoded Therapeutics
This biotechnology company develops precision genetic medicines for patients with severe neurological disorders, including Dravet syndrome.
Ultragenyx
This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.
Affinia Therapeutics
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.
Scenic Biotech
This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.